SG11201603469UA - Compositions and methods for the treatment of viral diseases with pde4 modulators - Google Patents

Compositions and methods for the treatment of viral diseases with pde4 modulators

Info

Publication number
SG11201603469UA
SG11201603469UA SG11201603469UA SG11201603469UA SG11201603469UA SG 11201603469U A SG11201603469U A SG 11201603469UA SG 11201603469U A SG11201603469U A SG 11201603469UA SG 11201603469U A SG11201603469U A SG 11201603469UA SG 11201603469U A SG11201603469U A SG 11201603469UA
Authority
SG
Singapore
Prior art keywords
compositions
treatment
methods
viral diseases
pde4 modulators
Prior art date
Application number
SG11201603469UA
Inventor
Jerome B Zeldis
Vikram Khetani
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of SG11201603469UA publication Critical patent/SG11201603469UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11201603469UA 2013-11-06 2014-11-05 Compositions and methods for the treatment of viral diseases with pde4 modulators SG11201603469UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361900489P 2013-11-06 2013-11-06
PCT/US2014/064047 WO2015069711A1 (en) 2013-11-06 2014-11-05 Compositions and methods for the treatment of viral diseases with pde4 modulators

Publications (1)

Publication Number Publication Date
SG11201603469UA true SG11201603469UA (en) 2016-05-30

Family

ID=51999519

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201603469UA SG11201603469UA (en) 2013-11-06 2014-11-05 Compositions and methods for the treatment of viral diseases with pde4 modulators

Country Status (14)

Country Link
US (1) US20160289188A1 (en)
EP (1) EP3065778A1 (en)
JP (1) JP2016540041A (en)
KR (1) KR20160068981A (en)
CN (1) CN105873611A (en)
AR (1) AR099283A1 (en)
AU (1) AU2014346877A1 (en)
CA (1) CA2929539A1 (en)
EA (1) EA201690937A1 (en)
IL (1) IL245511A0 (en)
MX (1) MX2016005808A (en)
PH (1) PH12016500824A1 (en)
SG (1) SG11201603469UA (en)
WO (1) WO2015069711A1 (en)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605914A (en) * 1993-07-02 1997-02-25 Celgene Corporation Imides
MXPA05005161A (en) * 2002-11-18 2005-07-22 Celgene Corp Methods of usig and compositions comprising (-)-3- (3, 4- dimethoxy -phenyl)-3 -(1-oxo-1, 3-dihydro- isoindol- 2-yl)- propionamide.
CN1452982A (en) * 2003-06-25 2003-11-05 上海兴康医药研究开发有限公司 Mucosa administrated Ribavirin prepn for preventing & curing SARS and its prepn process
CN1972684A (en) * 2004-04-23 2007-05-30 细胞基因公司 Methods of using and compositions comprising PDE4 modulators for the treatment and management of pulmonary hypertension
WO2007139150A1 (en) * 2006-05-30 2007-12-06 The University Of Tokushima ANTI-INFLUENZA VIRAL AGENT COMPRISING TNF-α INHIBITOR
MX2010002278A (en) * 2007-08-27 2010-03-17 Siga Technologies Inc Antiviral drugs for treatment of arenavirus infection.
US20100080807A1 (en) * 2008-09-26 2010-04-01 National Taiwan University Methods and Compositions for Treating Viral Hemorrhagic Fever
US20100297033A1 (en) * 2009-05-21 2010-11-25 Mcleay Matthew T Megaribavirin alone or combination of other antiviral, antioxidant and a perflubron emulsion for treatment of viral disease
US9408831B2 (en) * 2010-04-07 2016-08-09 Celgene Corporation Methods for treating respiratory viral infection
WO2012118599A1 (en) * 2011-02-28 2012-09-07 Emory University C-abl tyrosine kinase inhibitors useful for inhibiting filovirus replication

Also Published As

Publication number Publication date
JP2016540041A (en) 2016-12-22
US20160289188A1 (en) 2016-10-06
IL245511A0 (en) 2016-06-30
WO2015069711A1 (en) 2015-05-14
CA2929539A1 (en) 2015-05-14
KR20160068981A (en) 2016-06-15
AU2014346877A1 (en) 2016-05-26
MX2016005808A (en) 2016-07-18
EP3065778A1 (en) 2016-09-14
AR099283A1 (en) 2016-07-13
EA201690937A1 (en) 2017-02-28
CN105873611A (en) 2016-08-17
PH12016500824A1 (en) 2016-06-13

Similar Documents

Publication Publication Date Title
HRP20170945T1 (en) Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
HK1217021A1 (en) Combination therapy of antibodies against human csf-1r and antibodies against human pd-l1 csf-1r pd-l1
HK1248596A1 (en) Novel sez6 modulators and methods of use
HK1207636A1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
HK1222552A1 (en) Sobetirome in the treatment of myelination diseases
EP2988781A4 (en) Compositions and methods for the therapy and diagnosis of influenza
EP3038610A4 (en) Compositions and methods for the treatment of presbyopia
HK1210463A1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
HK1211290A1 (en) Heterocycle-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases
EP3086809A4 (en) Compositions and methods of treating ocular diseases
EP2945953A4 (en) Thiophene-substituted tetracyclic compounds and methods of use thereof for treatment of viral diseases
HK1220374A1 (en) Compositions and methods for the treatment of carboxyhemoglobinemia
EP3013834A4 (en) Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
EP3013334A4 (en) Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
HK1216721A1 (en) Uses and methods for the treatment of liver diseases or conditions
EP2994147A4 (en) Compositions and methods for the treatment of tinnitus
EP3068431A4 (en) Methods and compositions for the treatment of hcmv
PL3079684T3 (en) Compositions and methods for the treatment of diseases related to the renin-angiotensin-system
EP2943593A4 (en) Diagnosis and treatment of viral diseases
IL245511A0 (en) Compositions and methods for the treatment of viral diseases with pde4 modulators
AU2013901658A0 (en) Compositions and methods for the treatment of tinnitus
AU2013901208A0 (en) Compositions and methods for the treatment of herpes
GB201306413D0 (en) The local treatment of ophthalmic diseases
AU2013901514A0 (en) Formulation and methods for treatment of mental disorders
AU2013902004A0 (en) Compositions for Therapy and Methods of Treatment